Seattle Genetics, Inc.  and Genmab have entered an additional antibody-drug conjugate (ADC) collaboration under which Genmab will pay $11 million upfront for exclusive rights to use Seattle Genetics’ auristatin-based ADC technology with its HuMax-AXL, an antibody targeting multiple types of solid cancers. Seattle Genetics is also entitled to receive more than $200 million in potential milestones and royalties on worldwide sales of any resulting products.   Also, prior to Genmab’s ini...